Concordance of selected diagnoses of 355 HNC cases included in the pathology review by slide and pathologist.

<p>Concordance of selected diagnoses of 355 HNC cases included in the pathology review by slide and pathologist.</p

Concordance of selected diagnoses of 355 HNC cases included in the pathology review by slide and pathologist.

<p>Concordance of selected diagnoses of 355 HNC cases included in the pathology review by slide and pathologist.</p

Detailed description of the sectioning procedures.

<p>Detailed description of the sectioning procedures.</p

Schematic representation of the sectioning procedures.

<p>Schematic representation of the sectioning procedures.</p

Building Bridges in Dermatology: Proceedings of the 9th Skin Academy Symposium

<p><b>Article full text</b></p> <p><br> </p> <p>The full text of this article can be found here<b>. </b><a href="https://link.springer.com/journal/13555/7/1/suppl/page/1">https://link.springer.com/journal/13555/7/1/suppl/page/1</a></p><p></p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p><br></p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p

Summary according to HPV type of prevalence in 6MPI, risk of progression to CIN3+ lesion and chance of clearance.

<div><p>Dark-shaded boxes: high prevalence (>10%), high risk of progression (HR >20) or low chance of clearance (HR <0.85)</p> <p>Medium-shaded boxes: medium prevalence (5–10%), medium risk of progression (HR 5–20) or medium chance of clearance (0.85-<0.95)</p> <p>Light-shaded boxes: low prevalence (<5%), low risk of progression (HR <5) or high chance of clearance (HR ≥0.95)</p> <p>Definitions of high, medium and low prevalence, risk of progression and chance of clearance are arbitrary and are based on the results of the present study.</p> <p>6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus; HR: hazard ratio.</p></div

Cumulative chance of clearing a cervical HPV infection (prevalent and incident infections).

<div><p><b>3a. Duration of infection</b></p> <p><b>3b. HPV type (infection of any duration)</b></p> <p>Kaplan–Meier estimates of probability of clearance (%) were calculated for transient, less than 6-month persistent HPV infection (6MPI), 6MPI and overall (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0079260#pone-0079260-g003" target="_blank">Figure 3a</a>) or according the HPV types (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0079260#pone-0079260-g003" target="_blank">Figure 3b</a>): HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, other oncogenic HPV types and non-oncogenic HPV types.</p></div

Risk of progression of a 6MPI to CIN2+ or CIN3+ associated with the same HPV type.

<div><p><b>2a. CIN2+</b></p> <p><b>2b. CIN3+</b></p> <p>Kaplan–Meier Estimates of Cumulative Risk (%) of Developing CIN2+ Lesions (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0079260#pone-0079260-g002" target="_blank">Figure 2a</a>) or CIN3+ Lesions (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0079260#pone-0079260-g002" target="_blank">Figure 2b</a>) Associated with the Same HPV Type Were Calculated for HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, Other Oncogenic HPV Types and Non-Oncogenic HPV Types</p></div

Summary results for the six SNPs selected for replication in oral cancer GWAS. Ranking was based on the Bayesian False Discovery Probability (BFDP).

a)<p>Total number of cases and controls included in the final GWA analysis (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0036888#pone.0036888.s004" target="_blank">Table S2</a>).</p>b)<p>Total number of cases and controls included in the replication analysis.</p>c)<p>Major and minor alleles, with corresponding allele frequencies in controls.</p>d)<p>OR, 95% CI and p-values were estimated for the per-rare-allele log-additive genetic model by unconditional logistic regression, adjusting for sex and country (see methods).</p>e)<p>Prior probability of association (prior for the alternative hypothesis H₀) based on the ADAPT literature search (see methods).</p>f)<p>GWAS ranking based on p-values.</p>g)<p>The Bayesian False Discovery Probability (BFDP) was estimated based on the association results and the prior probability of association (see methods). The point BFDP estimate corresponds to 100 true susceptibility SNPs assumed to be included in the dataset that are evenly distributed across the prior categories. The range refers to a sensitivity analysis of the BFDP by varying the assumed number of true susceptibility SNPs in the dataset. The bottom and upper boundaries were estimated by assuming 500 and 50 true susceptibility SNPs, respectively.</p>h)<p>GWAS ranking based on BFDP estimates.</p>i)<p>OR, 95% CI and p-values were estimated for the per-rare-allele log-additive genetic model by unconditional logistic regression, adjusting for sex and study center (see methods).</p>j)<p>P-heterogeneity indicates differences in OR between the discovery and replication phases, and was derived from the Cochran's Q test.</p

Forest plot showing overall and stratified association results of the rs991316 SNP with oral cancer (oral cavity and oropharyngeal cancer).

<p>a) Apart from the OR for CT heterozygotes and TT homozygotes, which were estimated relative the major CC homozygotes, all OR and 95% CIs were estimated using the log-additive model, adjusting for age, gender and center. All subjects from the genome-wide and replication phases with available co-variates were included in this analysis (not generic controls). The overall OR for cancers of oral cavity and oropharynx is shown by the dotted vertical line. b) P for heterogeneity indicates differences in OR between strata and was derived from the Cochran's Q test. c) Never drinkers were subjects that either reported 0 g alcohol intake per day, or reported being never drinker, light drinkers consumed >0 and <6.06 g alc./day, intermediate drinkers consumed >6.06 and <46.3 g alc./day, and heavy drinkers consumed >46.3 g alc./day. d) Hypopharynx, larynx, and esophagus cases were not included in the analyses above.</p